Dynavax Technologies Corporation Share Price Nasdaq
Equities
US2681581029
Biotechnology & Medical Research
End-of-day quote
Other stock markets
|
||
- USD | - |
Sales 2024 * | 285M 23.73B | Sales 2025 * | 350M 29.17B | Capitalization | 1.49B 124B |
---|---|---|---|---|---|
Net income 2024 * | 18M 1.5B | Net income 2025 * | 48M 4B | EV / Sales 2024 * | 3.28 x |
Net cash position 2024 * | 556M 46.3B | Net cash position 2025 * | 683M 56.86B | EV / Sales 2025 * | 2.31 x |
P/E ratio 2024 * |
71.2
x | P/E ratio 2025 * |
31.6
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 99.69% |
Latest transcript on Dynavax Technologies Corporation
Managers | Title | Age | Since |
---|---|---|---|
Ryan Spencer
CEO | Chief Executive Officer | 46 | 01/05/01 |
David Novack
PSD | President | 62 | 25/13/25 |
Patricia Novy
CTO | Chief Tech/Sci/R&D Officer | - | 01/21/01 |
Members of the board | Title | Age | Since |
---|---|---|---|
Francis Cano
BRD | Director/Board Member | 79 | 03/09/03 |
Peggy Phillips
BRD | Director/Board Member | 70 | 01/06/01 |
Dan Kisner
BRD | Director/Board Member | 77 | 22/10/22 |
1st Jan change | Capi. | |
---|---|---|
+9.58% | 115B | |
+12.41% | 106B | |
-2.59% | 21.96B | |
-12.38% | 21.87B | |
-5.29% | 19.21B | |
-3.35% | 18.08B | |
-38.57% | 17.71B | |
+7.51% | 14.32B | |
+35.67% | 12.42B |